阿托品控制近视增长的研究进展

A review of atropine for the treatment of myopia

近年来青少年近视发生率逐年上升，并且呈低龄化趋势。目前，用于治疗和控制近视增长的方法很多，如框架眼镜、角膜塑形镜、药物等，治疗和控制效果各异。其中，阿托品在控制近视增长方面效果显著，高浓度（1％、0．5％、0．1％）阿托品可以有效抑制近视屈光度和眼轴的增长，但同时伴有一些由药物本身药理作用引起的不良反应，如畏光、视近模糊等，而低浓度（0．01％）阿托品在保留近视控制作用的同时，不良反应相对较轻，患者接受度较高。现就阿托品在控制近视增长方面的一些研究进展做一综述。

Recently, the incidence of myopia has been rising year by year among adolescents with a trend toward younger children. At present, some methods used in treating and controlling myopia are eyeglass spectacles, orthokeratology lenses, drugs, etc. Among these methods, the effect of atropine in high concentrations （1%, 0.5% and 0.1%） can effectively reduce the refractive error and axial length elongation of myopia. However, there are some side effects from its pharmacological activity, such as photophobia and near vision blur, etc. But these side effects are not present in low concentrations （0.01%）. This paper presents a simple summary of the use of atropine for the cure and control of myopia.